Blog
RSS FeedPosted by Michael Wonder on 07 Aug 2018
Prices for common cardiovascular drugs in the US are not consistently aligned with value
6 August 2018 - Health care reimbursement agencies in countries other than the US often rely on cost-effectiveness evidence for drug ...
Posted by Michael Wonder on 26 Jul 2018
Meningococcal vaccine rejected as not being "cost-effective"
25 July 2018 - With five cases of meningococccal disease now confirmed in Tasmania, questions are being asked about why the ...
Posted by Michael Wonder on 13 Jul 2018
U.S. ended value-based pricing plan for cancer drug because of doubts it would work
12 July 2018 - The Centers for Medicare and Medicaid Services ended a plan to pay for a $475,000 Novartis ...
Posted by Michael Wonder on 01 Jul 2018
FDA allows off-label health care economic discussions. Is there more to come?
29 June 2018 - The Trump administration has issued final guidance that allows drug companies and device makers to provide ...
Posted by Michael Wonder on 27 Jun 2018
CMS approves state proposal to advance specific Medicaid value-based arrangements with drug makers
27 June 2018 - First-of-its-kind approval for Oklahoma Medicaid will drive value. ...
Posted by Michael Wonder on 18 Jun 2018
Is ASCO sending mixed messages on cancer drug value?
13 June 2018 - According to IQVIA, U.S. spending on cancer drugs was $50 billion in 2017, which is almost ...
Posted by Michael Wonder on 13 Jun 2018
AMCP applauds FDA for final guidance on payer and manufacturer communications to improve patient access to emerging therapies
13 June 2018 - The Academy of Managed Care Pharmacy commends the U.S. FDA for issuing final guidance that clarifies ...
Posted by Michael Wonder on 12 Jun 2018
Statement from FDA Commissioner on new efforts to advance medical product communications to support drug competition and value-based health care
12 June 2018 - We’re living in a time of unparalleled scientific advancement. Innovative medical treatments continue to be developed ...
Posted by Michael Wonder on 01 Jun 2018
New analysis shows using ICER’s value assessments would limit access to life-saving medicines in Medicare Part B
31 May 2018 - 62 to 93% of Medicare Part B beneficiaries with serious, complex conditions could lose access to their ...
Posted by Michael Wonder on 15 May 2018
How to make a dent in crazy-high drug prices
11 May 2018 - Some of the most expensive medicines are among the least effective. Why does that make sense? ...
Posted by Michael Wonder on 09 May 2018
Evaluating and valuing drugs for rare conditions: no easy answers
9 May 2018 - We find ourselves in an era of unprecedented growth in the development and use of so-called “orphan” ...
Posted by Michael Wonder on 09 May 2018
Aligning price and value for drugs—potential disrupters of the PBM model
7 May 2018 - When the latest version of the iPhone comes out, customers can judge whether the price is "worth ...
Posted by Michael Wonder on 01 May 2018
Value-based pricing for drugs
30 April 2018 - In December 2017, the US FDA approved voretigene neparvovec-rzyl (Luxturna), a one-time genetic treatment manufactured by ...
Posted by Michael Wonder on 27 Apr 2018
IQWiG in dialogue on 15 June 2018: Do the new "estimand" strategies threaten the standards of benefit assessment?
26 April 2018 - Registration now possible/discussion about current method proposals of the EMA. ...
Posted by Michael Wonder on 24 Apr 2018
Value-based healthcare summit looks at a new health paradigm
24 April 2018 - The Medical Technology Association of Australia value-based healthcare summit is bringing together policy makers, patient advocates, ...